CANSINOBIO (06185) has announced its financial performance for the year 2025. The company reported revenue of approximately 1.059 billion yuan, representing a year-on-year increase of 28.43%. Annual profit was 27.873 million yuan, marking a turnaround from a loss to a profit compared to the previous year. Earnings per share stood at 0.11 yuan.

The shift to profitability was attributed to revenue growth, optimization of production costs, and improved operational efficiency. Since the launch of the quadrivalent meningococcal conjugate vaccine Menhycyx® and the bivalent meningococcal conjugate vaccine Menfycyx® in 2022, these two vaccines have provided more efficient and higher-quality options for preventing meningococcal disease in infants and young children.

In 2025, with the promotion and market introduction of the meningococcal vaccine products, the two conjugate vaccines generated sales revenue of approximately 967.7 million yuan, an increase of 21.9% compared to the previous year.

Furthermore, as of the report date, the supplemental drug application for Menhycyx® has been approved by the National Medical Products Administration, expanding the applicable age range to "children aged 3 months to 6 years (83 months)." This approval is expected to provide comprehensive protection for a broader pediatric population in the future. CANSINOBIO will also continue to advance the application to extend the use of Menhycyx® to individuals aged 7 to 59 years, aiming to maximize the value of its core product.